Clinical study of a C31G containing mouthrinse: effect on salivary microorganisms.
In vitro studies have demonstrated the antiplaque properties of C31G, a potent broad spectrum antimicrobial agent consisting of an equimolar mixture of alkyl dimethyl glycine and alkyl dimethyl amine oxide, buffered with citric acid. In this initial clinical study, C31G at concentrations of 0.05%, 0.1%, 0.2% and 0.5%. Listerine, and placebo were tested in a complete crossover design. Twelve subjects were evaluated, with a minimum of 2 days between treatments. Parameters monitored were salivary bacterial counts and saliva glycolysis. The 0.5% and 0.2% C31G mouthrinses significantly reduced total bacterial counts in saliva samples obtained up to and including three hours after rinsing, compared with counts obtained prerinsing or after placebo rinsing. Both 0.5%, and 0.2% C31G significantly inhibited glycolysis of salivary bacteria for up to 6 hours postrinsing, compared with pH values obtained prerinsing. 0.1% and 0.05% C31G exhibited little or no effect in either assay. Listerine showed a significant reduction in bacterial counts for up to 1 hour postrinsing, compared with prerinse counts, but the effect was less sustained. Listerine showed no significant inhibition of glycolysis at any time point. No tooth staining or altered taste sensation was noted with either product.
Corner
A M
AM
University of Pennsylvania School of Dental Medicine.
Brightman
V J
VJ
Cooper
S
S
Yankell
S L
SL
Malamud
D
D
D000328:Adult; D000704:Analysis of Variance; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects; D001622:Betaine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D003773:Dental Plaque / Q000517:prevention & control*; D004338:Drug Combinations; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage* / Q000494:pharmacology; D006019:Glycolysis / Q000187:drug effects; D006801:Humans; D009067:Mouthwashes / Q000008:administration & dosage* / Q000494:pharmacology; D012459:Salicylates / Q000008:administration & dosage / Q000494:pharmacology; D012463:Saliva / Q000382:microbiology*; D013291:Streptococcus / Q000187:drug effects*; D013729:Terpenes / Q000008:administration & dosage / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D005231:Fatty Acids, Unsaturated; D009067:Mouthwashes; D012459:Salicylates; D013729:Terpenes; D001622:Betaine; C057473:Listerine; C038360:C 31G